期刊文献+

益骨胶囊含药血清对成骨细胞骨保护蛋白mRNA表达的影响 被引量:2

Effect of Yigu capsule drug-containing serum on the expression of osteoprotegerin mRNA in osteoblasts
下载PDF
导出
摘要 目的:观察益骨胶囊含药血清对体外培养的大鼠成骨细胞骨保护蛋白mRNA的影响。方法:实验于2004-05/2005-02在广州暨南大学生命科学技术学院细胞与蛋白质工程实验室完成。选取12月龄SD雌性大鼠20只,随机分为2组。中药给药组(益骨胶囊由淫羊藿、当归、白芍、枸杞子等8味中药组成)和蒸馏水对照组,每组10只。运用大鼠灌胃的方法制备含药血清和对照血清,分离、培养新生大鼠的颅骨成骨细胞,传代后分为2组(含药血清组和空白血清对照组),每组8孔,分别在培养24,48h时用反转录聚合酶链反应技术测定特异性电泳条带所显示成骨细胞中骨保护蛋白mRNA的相对表达量,酶联免疫法检测48,72和96h时200mL/L终浓度培养上清中骨保护蛋白的浓度。结果:两组动物各10只,均无亡失,所取血清正常用于细胞培养。①成骨细胞在接种4h后可见部分细胞贴壁、伸展。随培养时间延长,细胞伸出较多突起,细胞形态为单核,多边形及梭形,培养2d细胞基本全部贴壁,主要为梭形或多边形,培养6d左右基本贴满瓶壁,呈铺路石样排列。单层铺满培养瓶后可出现重叠生长,传代细胞大约15d天左右开始形成矿化结节。②特异性电泳条带显示益骨胶囊含药血清培养后24h和48h成骨细胞骨保护蛋白mRNA的表达均高于空白血清对照组犤(0.196±0.015,0.236±0.016),(0.152±0.018,0.206±0.022),P<0.01犦;③200mL/L终浓度的益骨胶囊含药血清培养后48,72和96h成骨细胞骨保护蛋白的表达明显高于空白血清对照组犤(0.1230±0.0128,0.1681±0.0130,0.1983±0.0186),(0.1067±0.0106,0.1385±0.0126,0.1588±0.0121),P<0.01或P<0.05犦。结论:益骨胶囊含药血清具有促进成骨细胞表达骨保护蛋白的作用。提示益骨胶囊能够通过对成骨细胞的影响而对骨吸收环节具有抑制作用,但是否对其他信号通路也有作用尚待研究。 AIM:To observe the effects of Yigu capsule drug-containing serum on osteoprotegerin mRNA in rats' osteoblasts cultured in vitro.METHODS:The experiment was carried out in the Cell and Protein Engineering Laboratory,College of Life Science Technology,Jinan University from May 2004 to February 2005.Twenty male 12 month old SD rats were randomly divided into two groups:traditional Chinese medicine (Yigu capsule,which consisted of 8 Chinese herbs,wuch as epimedium,prepared rehmannia,wolfberry fruit,achyranthes root,etc.) group (n=10) and distilled water control group (n=10).The drug containing serum and control serum were prepared with the method of gastric perfusion,and the osteoblasts in skull of new born rats were separated and cultured.After passage,they were randomly divided into drug containing serum group (n=8) and control serum group (n=8),and then the relative expression value of osteoprotegerin mRNA in osteoblasts were determined with the technique of reverse transcription polymerase chain reaction specific electrophoresis strap at 24 and 48 hours of culture respectively,and the concentration of osteoprotegerin in supernatant fluid(end concentration of 200 mL/L) was detected with enzyme linked immunosorbent assay at 48,72 and 96 hours of culture respectively.RESULTS:No rat died in both groups (n=10 respectively),and the taken serum was normally used for cell cultivation.① Four hours after inoculation,stick to wall and extension of osteoblasts were observed.With the prolongation of culture,the osteoblasts extended more processus,the shape was mononuclear,polygon and fusiform shapes;Two days after cultivation,almost all the osteoblasts stuck to wall,the shapes were mainly polygon or fusiform;About 6 days after cultivation,the osteoblasts stuck to almost the complete wall of the bottle,arranged like slabstone;Overlapped growth occurred after the spread of single layer in the culture bottle,the passage cells began to mineralize and nod at about 15 days.② Specific electrophoresis strap showed that the expressions of osteoprotegerin mRNA in osteoblasts 24 and 48 hours after cultivation were higher in the Yigu capsule drug containing serum than in the blank serum[(0.196± 0.015,0.236± 0.016),(0.152± 0.018,0.206± 0.022),P< 0.01].③ The expressions of osteoprotegerin protein in osteoblasts 48,72 and 96 hours after cultivation were obviously higher in the Yigu capsule drug containing serum (end concentration of 200 mL/L) than in the blank serum[(0.123 0± 0.012 8,0.168 1± 0.013 0,0.198 3± 0.018 6),(0.106 7± 0.010 6,0.138 5 ± 0.012 6,0.158 8± 0.012 1),P< 0.01 or P< 0.05].CONCLUSION:Yigu capsule drug containing serum can promote the expression of osteoblasts,indicating that Yigu capsule has the role in inhibiting the link of bone resorption by its influence on osteoblasts,but whether it plays a role in other signal pathways still needs to be investigated.
出处 《中国临床康复》 CAS CSCD 北大核心 2005年第19期180-182,共3页 Chinese Journal of Clinical Rehabilitation
基金 国家自然科学基金资助项目(30472274) 广东省自然科学基金重点项目(04105837) 广东省科技攻关项目(2004B33001004)~~
  • 相关文献

参考文献10

  • 1张荣华,陈可冀,陆大祥,朱晓峰,马晓昌.益骨胶囊治疗绝经后骨质疏松症的临床研究[J].中国中西医结合杂志,2004,24(8):680-684. 被引量:34
  • 2舒晓春,张荣华,彭柯萍,朱晓峰,蔡宇.益骨胶囊对成骨细胞增殖影响的时效及量效关系研究[J].中药材,2003,26(9):644-647. 被引量:11
  • 3Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997;89(2):309-19.
  • 4王小斌,单其俊,马根山.骨保护素的研究进展[J].中国临床康复,2004,8(20):4066-4068. 被引量:3
  • 5Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397(6717):315-23.
  • 6Udagawa N, Takahashi N, Yasuda H, et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 2000;141(9):3478-84.
  • 7Ueland T, Brixen K, Mosekilde L, et al. Age-related changes in cortical bone content of insulin-like growth factor binding protein(IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study. J Clin Endocrinol Metab 2003;88(3):1014-8.
  • 8张忠荣,王爱民,王晓军,吴思宇,贺伟峰,王子明,唐颍.人骨保护素重组腺病毒抑制去势骨质疏松大鼠骨吸收作用的研究[J].中国临床康复,2004,8(36):8267-8269. 被引量:2
  • 9Bord S, Ireland DC, Beavan SR, et al. The effects of estrogen on osteoprotegerin,RANKL, and estrogen receptor expression in human, osteoblasts Bone 2003;32(2):136-41.
  • 10Chen XW, Garner SC, And JJ. lsoflavones regulate interleukin-6 and osteoprotegerin synthesis during osteoblast cell differentiation via an estrogen-receptor-dependent pathway. Biochemical Biophysical Research Communi 2002;295(2):417-22.

二级参考文献45

  • 1陈长勋,金若敏,贺劲松,李仪奎.用血清药理学实验方法观察附子的强心作用[J].中国中医药科技,1996,3(3):12-14. 被引量:53
  • 2[1]Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001; 86:631 -7
  • 3[2]Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novelsecreted protein involved in the regulation of bone density. Cell 1997; 89:309 -19
  • 4[3]Tsuda E, goto M, Mochisuke S, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Bio-chem Biophys Res Commun 1997; 234:137 -42
  • 5[4]Ten KB, h arrop J, Reddy M, et al. Charamerization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 1997; 204:35 -46
  • 6[5]Yasuda H, Shima N, Nakagawa N, et al. Osteoclas; t differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95(7): 3597 -602
  • 7[6]Yamaguchi K, Kinosaki M, Goto M, et al. Characterization of structured domains of human osteoclastogenesis inhibitory factor. J Biol Chem 1998; 273:5117 - 23
  • 8[7]Tomoyasu A, Goto M, Fujise N, et al. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. J Biochem Biophys Res Commun 1998; 245 (2): 382 - 387
  • 9[8]Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates ostoclast differentiation and avtivation. Cell 1998; 93:165 - 76
  • 10[9]Wong BR, Rho J, Arron J, et al. Trance is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997; 272:25190 - 4

共引文献43

同被引文献17

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部